Influence of pregnancy on outcomes of inflammatory bowel disease and treatment discontinuation

Table 2 Clinical outcomes and demographic data of patients with ulcerative colitis who continued and discontinued therapy, median (interquartile range)/n (%)

Characteristic	Continued treatment (n = 25)	Discontinued treatment (n = 12)	P value
Age at onset of disease, years	23 (11-32)	21.5 (14-25)	0.235
Total disease duration, months	109 (39.33-208.23)	75.07 (28.4-347.47)	0.364
Smoking			1
None	23 (92)	11 (91.7)
Existing/current	2 (8)	1 (8.3)
BMI (kg/m2)	21.45 (16.69-26.4)	20.44 (14.69-24.98)	0.549
Family history of IBD	2 (8)	1 (8.3)	1
Appendectomy		1 (8.3)	0.324
UC disease extension			0.699
Proctitis	2 (8)	1 (8.3)
Left-sided	14 (56)	5 (41.7)
Extensive	9 (36)	6 (50)
CRP (mg/L)	5 (1-30)	8.15 (0.75-20)	0.562
HB (g/dL)	12 (6.2-14.6)	10.1 (8.4-13)	0.037a
Albumin (g/dL)	4 (3.5-5.1)	4 (3.5-4.4)	0.033a
Mayo partial score	5 (1-9)	7 (4-8)	0.018a
Mayo endoscopic score	2 (0-3)	2.5 (2-3)	0.009a
Disease activation	6 (24)	9 (75)	0.005a
Current treatment	19 (76)	7 (58.3)	0.271
Mesalazine	14 (56)	7 (58.3)	0.893
Thiopurine	2 (8)		1
Biologics
Adalimumab	1 (4)		1
Infliximab	1 (4)		1
Vedolizumab	1 (4)		1
History of abortion	9 (36)	4 (33.3)	1
IUGR	2 (8)	1 (4)
Low birth weight	3 (12)	2 (8)

^aP < 0.05.

BMI: Body mass index; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CRP: C-reactive protein; HB: Hemoglobin; IUGR: Intrauterine growth retardation.